Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | CD44 | P16070 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22465809 | 0.98 | PNMT (0.53) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL29867656 | 0.93 | ASIC3 (0.55) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL120623 | 0.93 | ASIC3 (0.55) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| Hydrochloric Acid SCHEMBL4789548 | 0.91 | ASIC3 (0.53) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL18766202 | 0.89 | HTR2C (0.52) | ADRA2AADRA2BADRA2CDRD2DRD3 | |
| SCHEMBL1206291 | 0.84 | HTR2A (0.40) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL31514914 | 0.84 | HTR2A (0.40) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| Hydrochloric Acid SCHEMBL3710885 | 0.82 | HTR2A (0.39) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL22542171 | 0.81 | PNMT (0.55) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL13650345 | 0.81 | PNMT (0.55) | PNMTADRA2AADRA2BADRA2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227803-B1 | COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS | BELLUS HEALTH INTERNATIONAL LTD (CH) | 2010-05-05 | — | — | EP | claimed |
| US-6562836-B1 | Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 2003-05-13 | — | — | US | claimed |
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
| EP-3002278-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-7786174-B2 | Methods and compounds for inhibiting amyloid deposits | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-08-31 | — | — | US | disclosed |
| EP-1227803-B1 | COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS | BELLUS HEALTH INTERNATIONAL LTD (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-20080227767-A1 | Administering a compound that inhibits islet amyloid polypeptide-associated amyloid deposition, e.g., 8-hydroxy-5-quinolinesulfonic acid, sodium cyclohexylsulfamate, or octahydroisoquinolinyl-N-propanesulfonic acid; antidiabetic agents | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-09-18 | — | — | US | disclosed |
| US-7393875-B2 | Reducing islet amyloid polypeptide (IAPP) associated deposit; type II diabetes | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | PNMT 1090/4885ADRA2A 2513/4885ADRA2B 1565/4885 |
| US-20080227767-A1 | Administering a compound that inhibits islet amyloid polypeptide-associated amyloid deposition, e.g., 8-hydroxy-5-quinolinesulfonic acid, sodium cyclohexylsulfamate, or octahydroisoquinolinyl-N-propanesulfonic acid; antidiabetic agents | IAPP, APP, AMY2A | PNMT 2173/4885ADRA2A 2050/4885ADRA2B 1861/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | PNMT 1090/4885ADRA2A 2513/4885ADRA2B 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.